Incyte to Present Multiple Studies from Dermatology Portfolio at 2023 European Academy of Dermatology and Venereology (EADV) Congress
Incyte (Nasdaq:INCY) today announced multiple abstracts featuring new data from across its dermatology portfolio have been accepted for presentation at the upcoming European Academy of Dermatology and Venereology (EADV) Congress 2023 held October 11-14 in Berlin.
“We are pleased to add to the data supporting the use of ruxolitinib cream for patients living with vitiligo and atopic dermatitis (AD) through two late-breaking presentations – one on prolonged use of treatment in vitiligo patients with limited or no initial response, and the full results of our TRuE-AD3 trial in pediatric AD,” said Jim Lee, M.D., Ph.D., Group Vice President, Inflammation & Autoimmunity, Incyte. “Collectively, the data at this year's Congress, which also include new late-breaking data for povorcitinib in vitiligo, emphasize our ongoing efforts to advance treatment options for the Dermatology community."
Key abstracts from Incyte-sponsored programs include:
Late-breaking Oral Presentations
Vitiligo
Efficacy and Safety of Povorcitinib for Extensive Vitiligo: 52-Week Results from a Double-Blinded, Placebo-Controlled, Dose-Ranging Phase 2b Study (Abstract #6749. Session: D1T01.1A: Late Breaking News. Wednesday, October 11, 8:15 a.m. – 8:30 a.m. ET)
Efficacy of Prolonged Ruxolitinib Cream Treatment for Vitiligo Among Patients with Limited or No Initial Response at 6 Months (Abstract #6479. Session: D1T01.1I: Late Breaking News. Wednesday, October 11, 10:30 a.m. – 10:45 a.m. ET)
Atopic Dermatitis (AD)
A Phase 3 Study of Ruxolitinib Cream in Children Aged 2–<12 Years with Atopic Dermatitis (TRuE-AD3): 8-Week Analysis (Abstract #6746. Session: D3T01.3I: Late Breaking News. Friday, October 13, 10:30 a.m. – 10:45 a.m. ET)
Oral Presentations
Hidradenitis Suppurativa
Baseline Demographic and Disease Characteristics Associated with Achieving HiSCR with Povorcitinib: Secondary Analysis from a Phase 2, Randomized, Placebo-Controlled Clinical Trial (Abstract #2803. Session: FC02.1: Free Communications II. Thursday, October 12, 4:15 a.m. – 4:25 a.m. ET)
Impact of Povorcitinib on DLQI and DLQI Subdomains in Patients with Hidradenitis Suppurativa: Results from a Randomized, Placebo-Controlled Phase 2 Study (Abstract #2795. Session: FC02.2: Free Communications II. Thursday, October 12, 4:25 a.m. – 4:35 a.m. ET)
ePosters
Vitiligo
Effect of Ruxolitinib Cream on VASI-50 Achievement by Body Region Through Week 104 in Patients with Vitiligo: Analysis of the TRuE-V Long-Term Extension Phase 3 Study (Abstract #926)
Efficacy and Safety of Ruxolitinib Cream Through Week 104 in Patients with Vitiligo: Subgroup Analysis of the TRuE-V Long-Term Extension Phase 3 Study (Abstract #927)
Characterization and Treatment of Acne that Occurred Among Individuals with Vitiligo who Applied Ruxolitinib Cream in Two Randomized Phase 3 Trials (Abstract #2595)
Depression and Depressive Symptoms Among Persons Living with Vitiligo: Findings from the Global VALIANT Survey (Abstract #2572)
Treatment Satisfaction, Breaks and Cessation Among Patients Living with Vitiligo: Findings from the Global VALIANT Survey (Abstract #2579)
Retrospective Database Analysis on the Treatment Patterns in Patients with Vitiligo in Quebec, Canada (Abstract #2591)
Epidemiology and Comorbidity of Patients with Vitiligo in Germany (Abstract #3072)
AD
A Maximum-Use Trial of Ruxolitinib Cream in Children Aged ≥2 years to <12 Years with Atopic Dermatitis: 8-Week Analysis (Abstract #2551)
Rapid, Substantial and Sustained Reduction of Itch in Adults with Atopic Dermatitis Applying Ruxolitinib Cream — Clinical and Translational Results from the Open-Label Phase 2 SCRATCH-AD Study (Abstract #2813)
For full session details and data presentation listings, please see the EADV Congress 2023 (https://eadvcongress2023.org/scientific/) online program.
About Opzelura® (ruxolitinib) Cream 1.5%
Opzelura, a novel cream formulation of Incyte’s selective JAK1/JAK2 inhibitor ruxolitinib, approved by the U.S. Food & Drug Administration for the topical treatment of nonsegmental vitiligo in patients 12 years of age and older, is the first and only treatment for repigmentation approved for use in the United States. Opzelura is also approved in the U.S. for the topical short-term and non-continuous chronic treatment of mild to moderate atopic dermatitis (AD) in non-immunocompromised patients 12 years of age and older whose disease is not adequately controlled with topical prescription therapies, or when those therapies are not advisable. Use of Opzelura in combination with therapeutic biologics, other JAK inhibitors, or potent immunosuppressants, such as azathioprine or cyclosporine, is not recommended.
In Europe, Opzelura (ruxolitinib) cream 15mg/g is approved for the treatment of non-segmental vitiligo with facial involvement in adults and adolescents from 12 years of age.
Incyte has worldwide rights for the development and commercialization of ruxolitinib cream, marketed in the United States as Opzelura.
Opzelura and the Opzelura logo are registered trademarks of Incyte.
About Povorcitinib (INCB54707)
Povorcitinib (INCB54707) is an oral small-molecule JAK1 inhibitor currently in Phase 2 clinical trials for vitiligo, hidradenitis suppurativa (HS), prurigo nodularis, chronic spontaneous urticaria and asthma. Phase 3 studies in HS are also ongoing.
About Incyte Dermatology
Incyte’s science-first approach and expertise in immunology has formed the foundation of the company. Today, we are building on this legacy as we discover and develop innovative dermatology treatments to bring solutions to patients in need.
Our research and development efforts in dermatology are initially focused on leveraging our knowledge of the JAK-STAT pathway. We are exploring the potential of JAK inhibition for a number of immune-mediated dermatologic conditions with a high unmet medical need, including atopic dermatitis, vitiligo, hidradenitis suppurativa, lichen planus, lichen sclerosus and prurigo nodularis.
To learn more, visit the Dermatology section of Incyte.com.
About Incyte
Incyte is a Wilmington, Delaware-based, global biopharmaceutical company focused on finding solutions for serious unmet medical needs through the discovery, development and commercialization of proprietary therapeutics. For additional information on Incyte, please visit Incyte.com and follow @Incyte.
Forward-Looking Statements
Except for the historical information set forth herein, the matters set forth in this press release, including statements regarding the presentation of data from Incyte’s clinical development pipeline, whether or when any development compounds or combinations will be approved or commercially available for use in humans anywhere in the world outside of the already approved indications in specific regions, and Incyte’s goal of improving the lives of patients, contain predictions, estimates and other forward-looking statements.
These forward-looking statements are based on Incyte’s current expectations and subject to risks and uncertainties that may cause actual results to differ materially, including unanticipated developments in and risks related to: unanticipated delays; further research and development and the results of clinical trials possibly being unsuccessful or insufficient to meet applicable regulatory standards or warrant continued development; the ability to enroll sufficient numbers of subjects in clinical trials; determinations made by the FDA, EMA and other regulatory authorities; the efficacy or safety of Incyte’s products; the acceptance of Incyte’s products in the marketplace; market competition; sales, marketing, manufacturing and distribution requirements; and other risks detailed from time to time in Incyte’s reports filed with the Securities and Exchange Commission, including its annual report and its quarterly report on Form 10-Q for the quarter ended September 30, 2023. Incyte disclaims any intent or obligation to update these forward-looking statements.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230929594890/en/
Contact information
Media
Catalina Loveman
+1 302 498 6171
cloveman@incyte.com
Investors
Greg Shertzer
+1 302 498 4779
gshertzer@incyte.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Reibus International Announces CEO Transition29.11.2023 22:00:00 EET | Press release
Reibus International, the world’s largest online marketplace for metals, announces the appointment of Temy Mancusi-Ungaro as its new Interim Chief Executive Officer. The decision to bring Temy on board reflects a new era of investment in the company and Reibus’ continued commitment to driving innovation and growth in the metals industry. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20231129023580/en/ Temy Mancusi-Ungaro (Photo: Business Wire) With over 17 years of experience in the B2B Software industry, Temy is a seasoned operator who brings a proven track record of scaling innovative B2B companies, including Reachdesk, Electric, Yext, and CityGrid. He most recently held the position of CEO at Reachdesk, where his acumen for navigating the complexities of scaling a business led the company to be named among the top 100 fastest-growing products, according to G2, for three years in a row. "We are thrilled to welcome Temy to t
Tongxin Micro Making a Splash at TRUSTECH, and Unveiling the World’s First eSIM Solution Tailored for Smart POS Systems29.11.2023 20:00:00 EET | Press release
November 28th marks the grand opening of TRUSTECH 2023 in Paris, France. Tongxin Micro, an industry-leading semiconductor solution provider, makes an impressive debut, showcasing its technological advancements in identity recognition, telecommunications, and financial payments. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20231129462718/en/ (Photo: Business Wire) In the realm of identity recognition, Tongxin Micro brings its document chip solutions in compliance with international ICAO standards that boast the highest security levels globally, catering to such applications as seafarer’s passport and official passport. In telecommunications, a full array of products and terminal applications are displayed, including standard SIM, SWP-SIM, digital car keys based on SWP-SIM, and eSIM wearable devices. In the payment sector, Tongxin Micro’s innovative payment technologies draw significant attention, ranging from chip application
Gillette Gaming launches new creative concept, Hit Reset with Gillette, to encourage and inspire gamers and fans worldwide29.11.2023 19:15:00 EET | Press release
For over ten years, GilletteTM, the world’s largest male grooming company, has been helping gamers look and play their best, whether it be for gaming or everyday life. This year, Gillette is refreshing its approach and creating a new era of gaming with its newest campaign, “Hit Reset with Gillette” – encouraging the gaming community to hit reset after a night of gaming, come back a better player and look sharp for the day with a fresh shave. Hitting “reset” is a universal term in gaming and works perfectly with grooming – inviting gamers and fans to start their day looking and feeling their best, to be their best and most confident, whether it be in gaming or whatever the day has ahead. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20231129843095/en/ (Graphic: Business Wire) To further inspire the gaming community, Gillette will leverage its Gillette Gaming Alliance to create “Hit Reset with Gillette” content and host branded
Kahuna Workforce Solutions Secures $21 Million in Series B Funding from Resolve Growth Partners to Advance Skills Management Technology for Frontline Workers29.11.2023 19:08:00 EET | Press release
Kahuna Workforce Solutions, the leading provider of operational skills and competency management software, today announced a $21 million Series B funding round led by Resolve Growth Partners. This investment marks a significant milestone in Kahuna’s growth journey and solidifies the criticality of skills management for industries with technical frontline workforces. As organizations navigate an ever-evolving and complex landscape, understanding, validating, and aligning workforce skills to strategic business objectives is central to operating at the highest level. Kahuna is at the forefront of skills management technology, equipping organizations with actionable skill insights for effective assessment, training and development, and staffing and deployment initiatives, ultimately enabling resilient operations, improved productivity, and a more competitive workforce. Kahuna’s customer base of leading Fortune 500 energy, manufacturing, and field service organizations, and world-renowned h
OPPSCIENCE Reaffirms Its Commitment to Public Security by Supporting the AGIR Meetings Sponsored by French National Gendarmerie29.11.2023 18:45:00 EET | Press release
OPPSCIENCE, a leader in Intelligence Analysis Management (IAM), reaffirms its support for public security by sponsoring the AGIR event. Following the introduction of its latest version of SPECTRA, a software dedicated to law enforcement, during Milipol Paris, OPPSCIENCE contributes to accelerating the initiatives of the National Gendarmerie on the seek of innovations. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20231129543708/en/ The encounters at AGIR supported by OPPSCIENCE (Photo: Business Wire) MEETINGS AT AGIR: UNDERSTANDING THE NEEDS OF THE GENDARMERIE FOR LAW ENFORCEMENT Strengthening the dialogue between law enforcement and the technology industry is the goal of the AGIR exhibition (Accompagnement par la Gendarmerie de l’Innovation, de l’Industrie et de la Recherche). Initiated by the innovation unit of the National Gendarmerie, this exhibition enables innovators in the Gendarmerie community, specialized units, proj
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom